113 related articles for article (PubMed ID: 3323707)
1. [Monoclonal antibodies in pigmented lesions].
Puig L; Moreno A; Moragas JM
Med Cutan Ibero Lat Am; 1987; 15(6):481-8. PubMed ID: 3323707
[TBL] [Abstract][Full Text] [Related]
2. [Distribution of melanoma-associated antigens (HMB 45 and S 100) in benign and malignant melanocytic tumors of the conjunctiva].
Steuhl KP; Rohrbach JM; Knorr M
Klin Monbl Augenheilkd; 1991 Sep; 199(3):187-91. PubMed ID: 1753671
[TBL] [Abstract][Full Text] [Related]
3. [Nevus associated malignant melanomas--diagnostic validation and prognosis].
Stadler R; Garbe C
Hautarzt; 1991 Jul; 42(7):424-9. PubMed ID: 1938395
[TBL] [Abstract][Full Text] [Related]
4. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
5. Pigmented epithelioid melanocytoma.
Ward JR; Brady SP; Tada H; Levin NA
Int J Dermatol; 2006 Dec; 45(12):1403-5. PubMed ID: 17184238
[No Abstract] [Full Text] [Related]
6. Melanocytic nevi clinically simulating melanoma.
Makino E; Uchida T; Matsushita Y; Inaoki M; Fujimoto W
J Dermatol; 2007 Jan; 34(1):52-5. PubMed ID: 17204102
[TBL] [Abstract][Full Text] [Related]
7. [Comparative study of HMB-45 monoclonal antibody uptake on various benign and malignant melanocytic lesions].
Lampert A; Thomine E; Lauret P; Hemet J
Ann Pathol; 1993; 13(2):100-7. PubMed ID: 8363667
[TBL] [Abstract][Full Text] [Related]
8. Micro-anatomy related antigen expression in melanocytic lesions.
Meije CB; Mooi WJ; Le Poole IC; Van Muijen GN; Das PK
J Pathol; 2000 Apr; 190(5):572-8. PubMed ID: 10727983
[TBL] [Abstract][Full Text] [Related]
9. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
Fröhlich E; Mack AF; Garbe C; Klessen C
Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the diagnosis of pigmented tumors of the skin and factors leading to a decision to excise. Dermatologists of the Postgraduate Association of Haute-Normandie].
Collas H; Delbarre M; De Preville PA; Courville P; Neveu C; Dompmartin A; Balguerie X; Lemaistre B; Rzeznik JC; Thiebot B; Boullie MC; Bravard P; Michel Y; Krug M; Le Corvaisier-Pieto C; Young P; Thomine E; Boivin C; Ziade J; Pellerin A; Hellot MF; Leroy D; Lauret P; Benichou J; Joly P
Ann Dermatol Venereol; 1999; 126(6-7):494-500. PubMed ID: 10495858
[TBL] [Abstract][Full Text] [Related]
11. Principles of dermatoscopy of pigmented skin lesions.
Stolz W; Semmelmayer U; Johow K; Burgdorf WH
Semin Cutan Med Surg; 2003 Mar; 22(1):9-20. PubMed ID: 12773010
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
Chwirot BW; Kuźbicki Ł
Melanoma Res; 2007 Jun; 17(3):139-45. PubMed ID: 17505259
[TBL] [Abstract][Full Text] [Related]
13. Diagnosing and treating congenital melanocytic nevus simulating malignant melanoma.
Kovach R; Hochberg J; Ardenghy M; Deangelis R; Welton W
W V Med J; 1996; 92(4):191-3. PubMed ID: 8772404
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
15. [Diagnosis of pigmented skin lesions: how to recognize a malignant melanoma].
Giard RW; Neumann HA
Ned Tijdschr Geneeskd; 2004 Nov; 148(46):2261-7. PubMed ID: 15584540
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of microtubule-associated protein 2 in melanocytic skin lesions.
Gambichler T; Rotterdam S; Radkowski K; Altmeyer P; Kreuter A
Am J Clin Pathol; 2009 May; 131(5):710-4. PubMed ID: 19369632
[TBL] [Abstract][Full Text] [Related]
17. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000.
Lehmann JM; Holzmann B; Breitbart EW; Schmiegelow P; Riethmüller G; Johnson JP
Cancer Res; 1987 Feb; 47(3):841-5. PubMed ID: 3542195
[TBL] [Abstract][Full Text] [Related]
18. Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi.
Friedman RJ; Rigel DS; Kopf AW; Lieblich L; Lew R; Harris MN; Roses DF; Gumport SL; Ragaz A; Waldo E; Levine J; Levenstein M; Koenig R; Bart RS; Trau H
Arch Dermatol; 1983 Jun; 119(6):455-62. PubMed ID: 6859885
[TBL] [Abstract][Full Text] [Related]
19. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.
Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ
Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024
[TBL] [Abstract][Full Text] [Related]
20. Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens.
Natali PG; Bigotti A; Cavaliere R; Nicotra MR; Ferrone S
J Natl Cancer Inst; 1984 Jul; 73(1):13-24. PubMed ID: 6376904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
